
    
      As a secondary objective, this study also aims to establish the tissue concentration of
      ranibizumab when delivered via subconjunctival injection in patients undergoing pterygium
      excision and to determine the effects of ranibizumab on conjunctival healing, corneal
      epithelial healing, and wound dehiscence.
    
  